Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia
NCT06516679Phase 2Recruiting
- Sponsor
- Yonsei University
- Start
- Dec 2024
- Primary completion
- Aug 2032
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daunorubicin in lymphoid leukemia, sponsored by Yonsei University. Started Dec 2024; status: recruiting.
02
Drugs
daunorubicin
03
Conditions
lymphoid leukemia
Beyond the preview
Go deeper on NCT06516679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06516679.